早期乳腺癌患者化疗骨髓抑制与药物疗效关系的分析

发布时间：2018-01-22 07:07

  本文关键词： 乳腺癌 化疗 药物不良反应 骨髓抑制　出处：《中国临床药理学杂志》2017年19期 　论文类型：期刊论文

【摘要】：目的分析乳腺癌患者化疗骨髓抑制与预后的关系。方法检索Pub Med,EMbase和Cochrane数据库,进行系统性评价和Meta分析,使用固定效应模型或随机效应模型合并风险比(HR)和95%置信区间(95%CI)。结果本研究纳入9篇研究,共计9103名早期乳腺癌患者。相比于未出现骨髓抑制的患者,骨髓抑制的患者无病生存期(DFS)(HR:0.65,95%CI:0.54~0.79)显著延长,但总生存期(OS)延长(HR:0.69,95%CI:0.47~1.03)不显著。但重度骨髓抑制的患者在OS(HR:0.84,95%CI:0.75~0.95)和DFS(HR:0.67,95%CI:0.49~0.92)均显著获益。结论化疗诱导的血液学毒性可以作为早期乳腺癌的有效的标志之一,有助于判断药效和制定治疗决策。
[Abstract]:Objective to analyze the relationship between chemotherapy bone marrow suppression and prognosis in breast cancer patients. Methods Pub Medbase and Cochrane databases were searched for systematic evaluation and Meta analysis. The fixed effect model or stochastic effect model was used to combine the risk ratio (HRR) and the 95% confidence interval (95 CI). Results 9 studies were included in this study. A total of 9103 patients with early breast cancer. Compared with those without bone marrow suppression, the disease-free survival time of patients with bone marrow suppression was 0.65. 95 CI: 0.54 0.79) significantly longer, but the total survival time was prolonged by HR0: 0.69. 95 CI: 0.47 + 1.03) not significantly. But the patients with severe bone marrow suppression were in OS(HR:0.84. 95 CI: 0. 75 and 0. 95) and DFS(HR:0.67. Conclusion Hematological toxicity induced by chemotherapy can be used as one of the effective markers for early breast cancer, which is helpful to judge drug efficacy and make treatment decision.
【作者单位】： 北京大学第一医院药剂科;北京大学医学部药学院药事管理与临床药学系;
【分类号】：R737.9
【正文快照】： (1.北京大学第一医院药剂科,北京100034;2.北京大学医学部药学院药事管理与临床药学系,北京100191)FAN Hong-wei1,2,XIANG Qian1,ZHANG Zhuo1,2,CUI Yi-min1(1.Department of Pharmacy,PekingUniversity First Hospital,Beijing 100034,China;2.Department of PharmacyAdminis，

本文编号：1454034